U.S. health authorities endorse a more convenient approach to preventing cervical cancer, which is not widely available in Canada. The Health Resources and Services Administration has released new guidelines to make at-home self-testing kits for human papillomavirus (HPV) more accessible to women and individuals assigned female at birth. This shift moves away from the conventional Pap test in favor of HPV tests that can be conducted by either a healthcare provider or self-administered.
Early detection of cervical cancer through regular screening leads to a 90 percent five-year survival rate. While many Canadian jurisdictions now recommend HPV screening instead of the Pap test for preventing cervical cancer, self-administered tests are primarily available only in British Columbia. The at-home HPV testing kits function similarly to rapid COVID-19 tests, involving a swab to collect a specimen from the vagina without the need for a speculum or cervix scraping.
Unlike COVID-19 tests with rapid results, HPV screening samples must be sent to a lab for analysis. Self-collection not only offers privacy and convenience but also encourages more individuals, especially those who have never been screened or do so infrequently, to undergo HPV testing. The accuracy of HPV testing in detecting the virus is over 90 percent, which surpasses the accuracy of Pap smears that screen for abnormal cervical cells.
HPV causes nearly all cases of cervical cancer, with specific strains responsible for a significant portion of cases globally. A positive HPV test doesn’t guarantee cancer development but may prompt further examinations, potentially including a Pap test. However, there are rare instances where HPV testing may not detect certain cervical cancers. Health Canada recommends Pap tests every three years and HPV screening every five years.
British Columbia initiated a self-screening program for cervical cancer in January 2024, with other provinces like Prince Edward Island, Alberta, Manitoba, and Newfoundland and Labrador conducting self-screening pilot projects. Ontario offers HPV self-testing, although it’s not covered under the provincial insurance program. Private companies may provide kits at a cost, depending on the province.
In the U.S., the new recommendations grant women and individuals assigned female at birth aged 30 to 65, with average cervical cancer risk, the option to self-test for HPV. Most private insurance companies will be mandated to cover the test costs starting January 1, 2027. Individuals can still choose to have a healthcare provider conduct HPV tests or Pap smears.
The American Cancer Society reports around 13,000 new cervical cancer cases annually in the U.S., resulting in roughly 4,300 deaths. HPV infections are common, with Health Canada indicating that 75 percent of sexually active individuals will contract at least one HPV infection in their lifetime. Vaccines targeting carcinogenic HPV strains have contributed to a decline in cases, although recent evidence suggests a plateau in progress.
Cervical cancer rates in Canada declined from 1984 to 2005 but have plateaued since then, with preventable deaths still occurring. Efforts to lower cervical cancer rates include wider access to HPV testing and vaccination.